Leukocyte miR-223-3p is not associated with altered platelet responses to clopidogrel in patients with coronary artery disease

VernacularTitle:冠心病患者白细胞miR-223-3p水平与氯吡格雷治疗后的血小板反应无关
Author: Wenjian XIE ¹ ; Qian YIN ; Mengran ZHANG ; Shengnan LI ; Shaoliang CHEN
Author Information

1. 南京医科大学附属南京医院心内科
Keywords: clopidogrel; platelet; coronary artery disease; miR-223
From: Journal of Central South University(Medical Sciences) 2018;43(4):421-427
CountryChina
Language:Chinese
Abstract: Objective:To investigate the potential correlation between miR-223 level in leukocytes and platelet responses to clopidogrel in patients with coronary artery disease.Methods:A cohort of 188 outpatients,who conducted percutaneous coronary intervention (PCI) and received dual antiplatelet therapy,were recruited.The patient's electronic health data were collected,and their blood samples were obtained for measurement of adenosine diphosphate (ADP)-induced whole-blood platelet aggregation.Extreme cases ofplatelet responses to clopidogrel (ultra-vs.non-responder) were measured with miR-223-3p levels in leukocytes.Results:Both groups had similar miR-223-3p levels in leukocytes.There were no significant differences in other demographic and clinical data except for metrics of ADP-induced whole-blood platelet aggregation between the 2 group.Conclusion:MiR-223-3p in peripheral leukocytes is not associated with the altered platelet responses to clopidogrel in PCI outpatients.